Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 115

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 115
---
Investing in our common stock is speculative and
illiquid and involves a high degree of risk including the risk of a loss of your entire investment. You should carefully consider the
risks and uncertainties described below and the other information contained in this Annual Report on Form 10-K (“Report”)
before investing in our common stock. The risks set forth below are not the only ones facing us. Additional risks and uncertainties may
exist that could also adversely affect our business, operations and prospects. If any of the following risks actually materialize, our
business, financial condition, prospects and/or operations could suffer. In such event, the value of our common stock could decline, and
you could lose all or a substantial portion of the money that you pay for our common stock.

Unless the context otherwise requires, references
to the “Company,” the “combined company,” “Mosaic,” “we,” “our,” or “us”
in this Report refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries (formerly known as Patriot Scientific Corporation). References
to “PTSC” refer to Patriot Scientific Corporation prior to the completion of the Reverse Merger and references to “Private
Mosaic” refer to privately held Mosaic ImmunoEngineering, Inc. prior to the completion of the Reverse Merger.

Risks Related
to Our Operations 

While the Company’s financial statements
have been prepared on a going concern basis, we do not currently have sufficient working capital to fund our existing liabilities or any
planned operations for the next twelve months and we may be required to cease our operations altogether if we are unable to secure sufficient
funding. 

There is substantial doubt about our ability to continue
as a going concern, as we currently do not have adequate financial resources to fund our existing liabilities or potential future operations
for at least twelve months from the filing of this Report. As of December 31, 2024, the Company had incurred operating losses since inception,
and continues to generate losses from operations, and has cash and equivalents of $115,019, an accumulated deficit of $8,838,320 and current
liabilities of $5,537,270. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve
months from the date hereof and we would need to raise additional capital to continue our operations and to implement our business plan,
which capital is unlikely to be available on favorable terms or at all. These matters raise substantial doubt about the Company’s